<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">N Am J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">N Am J Med Sci</journal-id><journal-id journal-id-type="publisher-id">NAJMS</journal-id><journal-title-group><journal-title>North American Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">2250-1541</issn><issn pub-type="epub">1947-2714</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27298819</article-id><article-id pub-id-type="pmc">4899964</article-id><article-id pub-id-type="publisher-id">NAJMS-8-229</article-id><article-id pub-id-type="doi">10.4103/1947-2714.183015</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>A Novel Way of Treating Multidrug-resistant Enterococci</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Desai</surname><given-names>Hem</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Pasha</surname><given-names>Ahmed Khurshid</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><italic>Department of Internal Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA</italic></aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Hem Desai, 3300 N Paseo De Los Rios, Apartment 22204, Tucson - 85712, Arizona, USA. E-mail: <email xlink:href="hdesai@deptofmed.arizona.edu">hdesai@deptofmed.arizona.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2016</year></pub-date><volume>8</volume><issue>5</issue><fpage>229</fpage><lpage>231</lpage><permissions><copyright-statement>Copyright: &#x000a9; North American Journal of Medical Sciences</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Context:</title><p>Daptomycin is the only antibiotic available with <italic>in vitro</italic> bactericidal activity against vancomycin-resistant enterococci (VRE). Its increased use has resulted in cases of decreased daptomycin efficacy. Recent <italic>in vitro</italic> studies have shown effective use of beta (&#x003b2;)-lactam and daptomycin antibiotics, as a combination therapy, in the treatment of VRE. We describe a case of effective treatment in a patient with VRE infection using dual ampicillin and daptomycin therapy that shows bench-to-bedside application of the abovementioned finding.</p></sec><sec id="st2"><title>Case Report:</title><p>A 76-year-old gentleman with a history of bilateral arthroplasty was admitted with a swollen left knee. Blood cultures were positive for <italic>Enterococcus faecium</italic>. Left knee joint aspiration showed leukocytosis and alpha defensins. Extensive imaging did not show any other source of infection. Culture sensitivity results showed multidrug-resistant enterococci sensitive to daptomycin. The patient was started on intravenous (IV) daptomycin. His left knee prosthesis was explanted and a spacer was placed. The patient continued to be bacteremic for 10 days after removing the knee prosthesis. The patient was trialed on combination IV ampicillin and daptomycin. His blood culture turned negative 2 days later. The patient was discharged home to continue 6 weeks of IV ampicillin and daptomycin.</p></sec><sec id="st3"><title>Conclusion:</title><p>The exact mechanism of the daptomycin/ampicillin synergy effect is unclear. Current hypothesis suggests that ampicillin causes a reduction in the net positive charge of the bacterial surface, possibly by releasing lipoteichoic acid (LTA) from the cell wall. This process increases the ability of the cationic daptomycin/calcium complex to bind to the cell wall more effectively. Our case shows the clinical application of the same. A prospective randomized control trial to explore the effectiveness of dual antibiotic therapy <italic>in vivo</italic> is needed. If proven, daptomycin/&#x003b2;-lactam can become a standard of care to treat VRE and decrease daptomycin nonsusceptibility.</p></sec></abstract><kwd-group><kwd>Daptomycin/beta (&#x003b2;)-lactam</kwd><kwd>daptomycin nonsusceptibility</kwd><kwd>vancomycin-resistant enterococci</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>Context</title><p>Accounting for almost 10% of total bloodstream infections, <italic>Enterococcus</italic> is the fourth most common pathogen responsible for bloodstream infections in North America.[<xref rid="ref1" ref-type="bibr">1</xref>] Of those total number of <italic>Enterococcus</italic> infections, 25% are resistant to vancomycin.[<xref rid="ref2" ref-type="bibr">2</xref>] Vancomycin-resistant enterococci (VRE) infections have been associated with increased mortality and morbidity.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] In patients infected with VRE, the odds of death are 2.5 times higher compared with vancomycin-susceptible enterococci.[<xref rid="ref3" ref-type="bibr">3</xref>] Most of these antibiotics are bacteriostatic and associated with extensive drug-drug interactions.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Daptomycin is the only antibiotic available with <italic>in vitro</italic> bactericidal activity against VRE.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>] Daptomycin is being increasingly used, especially in the critically ill and immunosuppressed, even though it is not approved by the Food and Drug Administration (FDA).[<xref rid="ref11" ref-type="bibr">11</xref>] There have been reports of daptomycin nonsusceptible enterococci emergence during monotherapy.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>] Studies have shown that 2&#x02013;3% of VRE cases may be nonsusceptible to daptomycin.[<xref rid="ref13" ref-type="bibr">13</xref>] In those cases of resistant organisms, there are no other antibiotic treatment options. There have been recent <italic>in vitro</italic> studies showing effective use of beta (&#x003b2;)-lactams and daptomycin on daptomycin nonsusceptible enterococci.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] We describe a case of effective treatment in a patient with vancomycin-resistant <italic>Enterococcus faecium</italic> with dual ampicillin and daptomycin therapy that shows bench-to-bedside application of the abovementioned finding.</p></sec><sec id="sec1-2"><title>Case Presentation</title><p>A 76-year-old gentleman with a past medical history significant for extensive coronary artery disease and bilateral arthroplasty was admitted with the complaint of left knee swelling. He was afebrile on presentation. His left knee was erythematous, tender, and swollen compared to the right knee. Arthrocentesis was positive for alpha defensins with white blood cell (WBC) count of 18,000/uL. Fluid culture was negative. No crystalopathy was identified. Blood cultures were positive for <italic>Enterococci faecium</italic>. Transesophageal echocardiogram (TEE) was performed to rule out infective endocarditis and was negative.</p><p>The VRE, found in blood culture, were sensitive to daptomycin with 1:2 dilutions and resistant to ampicillin with 1:32 dilution. The patient was started on intravenous (IV) daptomycin 6 mg/kg daily. His left knee prosthesis was explanted and a spacer was placed on the fourth day of admission. Blood cultures were performed every other day to assess the antibiotic response. His blood cultures continued to grow VRE for 10 days after the explantation of the prosthesis. Extensive imaging was performed to find the source of infection. A whole body nuclear-tagged WBC scan did not show any signs of persistent infection. Magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis with and without contrast failed to show any focus of infection. Arthrocentesis of the right knee and repeat TEE were negative as well. Due to persistent bacteremia, the patient was tried on a combination of IV ampicillin and daptomycin. On the second day of the combined therapy, the next set of blood cultures were obtained and were negative for the first time since admission. Repeat blood cultures continued to be negative for 7 more days. He was eventually discharged with the peripherally inserted central catheter (PICC) line to continue 6 weeks of IV ampicillin and daptomycin.</p></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>This case showed an interesting clinical application of combination ampicillin and daptomycin to combat daptomycin nonsusceptible organisms. This phenomenon had been described mostly in <italic>in vitro</italic> studies.</p><p>Sakoulas <italic>et al</italic>. demonstrated a threefold decrease in daptomycin minimum inhibitory concentration (MIC), when VRE strain was grown in a medium containing 50 mg/L ampicillin and 100 mg/L ampicillin.[<xref rid="ref14" ref-type="bibr">14</xref>] However, the exact mechanism of the daptomycin/ampicillin synergistic effect is unclear at this time. The current hypothesis suggested that ampicillin causes a reduction in the net positive charge of the bacterial surface by releasing lipoteichoic acid (LTA) from the cell wall. The loss of LTA released cell autolysins that caused bacterial cell wall destabilization. More importantly, the reduction in cell wall positive charge appeared to allow the cationic daptomycin/calcium complex to bind more effectively to the cell wall. In a fluorescence-labeled daptomycin assay, this mechanism was supported as ampicillin pretreatment that resulted in an increase in daptomycin binding.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref16" ref-type="bibr">16</xref>]</p><p>Although, difficult to prove that in the current case, the clearance of bacteremia was related to the abovementioned mechanism, the patient continued to be bacteremic for 10 days while being treated with daptomycin monotherapy. With the addition of ampicillin, blood cultures drawn a couple of days after were negative and remained negative. This was similarly described in the report by Sakoulas <italic>et al</italic>., where a patient with persistent bacteremia refractory to 7 days of daptomycin/linezolid cleared the infection within 24 h of starting dual high-dose daptomycin and ampicillin.[<xref rid="ref14" ref-type="bibr">14</xref>] In a multiple hospitals study, Moise <italic>et al</italic>. showed a significantly higher daptomycin monotherapy failure when daptomycin MIC values were 3&#x02013;4 &#x000b5;g/L, compared to MIC &#x0003c;2 &#x000b5;g/L (<italic>P</italic> = 0.005). When comparing the two different MIC groups in patients treated with &#x003b2;-lactam/daptomycin dual therapy, treatment failure was not significantly different (<italic>P</italic> = 0.417).[<xref rid="ref15" ref-type="bibr">15</xref>] This may be evidence to suggest that adjunct ampicillin may be indicated in infections where daptomycin MIC is 3&#x02013;4.</p><p>Additionally, our case shows that <italic>in vitro</italic> drug susceptibility testing may not accurately translate into clinical potency. Even though the enterococcus isolate was resistant to ampicillin, the addition of ampicillin resulted in effective clearance of the patient's bacteremia, increasing the <italic>in vivo</italic> potency of daptomycin.</p><p>Other studies have described increased daptomycin efficacy with the addition of ceftaroline, a cephalosporin to which enterococci are intrinsically resistant.[<xref rid="ref17" ref-type="bibr">17</xref>] Dual antibiotic therapy with ampicillin and daptomycin additionally appeared to be effective in treating methicillin-resistant <italic>staphylococcus aureus</italic>.[<xref rid="ref18" ref-type="bibr">18</xref>]</p></sec><sec sec-type="conclusions" id="sec1-4"><title>Conclusion</title><p>Daptomycin is a potent bactericidal antibiotic. With the increased prevalence of VRE related infections, daptomycin may be the last line of defense against enterococci. Increasing prevalence of daptomycin nonsusceptible enterococci presents an added challenge for treating such life-threatening infections. A few <italic>in vitro</italic> experiments have studied the increased efficacy of daptomycin in the presence of &#x003b2;-lactam antibiotics. A prospective randomized control trial to explore the effectiveness of dual antibiotic therapy <italic>in vivo</italic> is needed. Further studies to assess synergistic effect of different antibiotics with daptomycin should be assessed. As multidrug-resistant organisms are becoming more common, it would be worthwhile to investigate synergistic antibiotic therapy. If proven, daptomycin/&#x003b2;-lactam can become a standard of care to treat VRE and can decrease daptomycin nonsusceptibility.</p><sec id="sec2-1"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-2"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshpande</surname><given-names>LM</given-names></name><name><surname>Fritsche</surname><given-names>TR</given-names></name><name><surname>Moet</surname><given-names>GJ</given-names></name><name><surname>Biedenbach</surname><given-names>DJ</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name></person-group><article-title>Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: A report from the SENTRY antimicrobial surveillance program</article-title><source>Diagn Microbiol Infect Dis</source><year>2007</year><volume>58</volume><fpage>163</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17368801</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>BE</given-names></name></person-group><article-title>Vancomycin-resistant enterococcal infections</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>710</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10706902</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiazGranados</surname><given-names>CA</given-names></name><name><surname>Zimmer</surname><given-names>SM</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Jernigan</surname><given-names>JA</given-names></name></person-group><article-title>Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A meta-analysis</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41</volume><fpage>327</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16007529</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>AM</given-names></name><name><surname>Zilberberg</surname><given-names>MD</given-names></name></person-group><article-title>Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006</article-title><source>Infect Control Hosp Epidemiol</source><year>2009</year><volume>30</volume><fpage>184</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19125679</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerson</surname><given-names>SL</given-names></name><name><surname>Kaplan</surname><given-names>SL</given-names></name><name><surname>Bruss</surname><given-names>JB</given-names></name><name><surname>Le</surname><given-names>V</given-names></name><name><surname>Arellano</surname><given-names>FM</given-names></name><name><surname>Hafkin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hematologic effects of linezolid: Summary of clinical experience</article-title><source>Antimicrob Agents Chemother</source><year>2002</year><volume>46</volume><fpage>2723</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12121967</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>TD</given-names></name><name><surname>Lau</surname><given-names>TT</given-names></name><name><surname>Ensom</surname><given-names>MH</given-names></name></person-group><article-title>Serotonergic and adrenergic drug interactions associated with linezolid: A critical review and practical management approach</article-title><source>Ann Pharmacother</source><year>2013</year><volume>47</volume><fpage>543</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">23548646</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>KM</given-names></name><name><surname>Rebuck</surname><given-names>JA</given-names></name><name><surname>Rupp</surname><given-names>ME</given-names></name></person-group><article-title>Arthralgias and myalgias related to quinupristin-dalfopristin administration</article-title><source>Clin Infect Dis</source><year>2001</year><volume>32</volume><fpage>e83</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11181142</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poutsiaka</surname><given-names>DD</given-names></name><name><surname>Skiffington</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>KB</given-names></name><name><surname>Hadley</surname><given-names>S</given-names></name><name><surname>Snydman</surname><given-names>DR</given-names></name></person-group><article-title>Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients</article-title><source>J Infect</source><year>2007</year><volume>54</volume><fpage>567</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17188750</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybak</surname><given-names>MJ</given-names></name><name><surname>Hershberger</surname><given-names>E</given-names></name><name><surname>Moldovan</surname><given-names>T</given-names></name><name><surname>Grucz</surname><given-names>RG</given-names></name></person-group><article-title><italic>In vitro</italic> activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and-resistant strains</article-title><source>Antimicrob Agents Chemother</source><year>2000</year><volume>44</volume><fpage>1062</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10722513</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alder</surname><given-names>JD</given-names></name></person-group><article-title>Daptomycin: A new drug class for the treatment of Gram-positive infections</article-title><source>Drugs Today (Barc)</source><year>2005</year><volume>41</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15821781</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whang</surname><given-names>DW</given-names></name><name><surname>Miller</surname><given-names>LG</given-names></name><name><surname>Partain</surname><given-names>NM</given-names></name><name><surname>McKinnell</surname><given-names>JA</given-names></name></person-group><article-title>Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>5013</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23896468</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JS</given-names><suffix>2nd</suffix></name><name><surname>Owens</surname><given-names>A</given-names></name><name><surname>Cadena</surname><given-names>J</given-names></name><name><surname>Sabol</surname><given-names>K</given-names></name><name><surname>Patterson</surname><given-names>JE</given-names></name><name><surname>Jorgensen</surname><given-names>JH</given-names></name></person-group><article-title>Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>1664</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15793168</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelesidis</surname><given-names>T</given-names></name><name><surname>Humphries</surname><given-names>R</given-names></name><name><surname>Uslan</surname><given-names>DZ</given-names></name><name><surname>Pegues</surname><given-names>DA</given-names></name></person-group><article-title>Daptomycin nonsusceptible enterococci: An emerging challenge for clinicians</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>228</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">21288849</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakoulas</surname><given-names>G</given-names></name><name><surname>Bayer</surname><given-names>AS</given-names></name><name><surname>Pogliano</surname><given-names>J</given-names></name><name><surname>Tsuji</surname><given-names>BT</given-names></name><name><surname>Yang</surname><given-names>SJ</given-names></name><name><surname>Mishra</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>838</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22123698</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moise</surname><given-names>PA</given-names></name><name><surname>Sakoulas</surname><given-names>G</given-names></name><name><surname>McKinnell</surname><given-names>JA</given-names></name><name><surname>Lamp</surname><given-names>KC</given-names></name><name><surname>DePestel</surname><given-names>DD</given-names></name><name><surname>Yoon</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Clinical outcomes of daptomycin for vancomycin-resistant enterococcus bacteremia</article-title><source>Clin Ther</source><year>2015</year><volume>37</volume><fpage>1443</fpage><lpage>53.e2</lpage><pub-id pub-id-type="pmid">25982687</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravetti</surname><given-names>AL</given-names></name><name><surname>Mesnage</surname><given-names>S</given-names></name><name><surname>Lefort</surname><given-names>A</given-names></name><name><surname>Chau</surname><given-names>F</given-names></name><name><surname>Eckert</surname><given-names>C</given-names></name><name><surname>Garry</surname><given-names>L</given-names></name><etal/></person-group><article-title>Contribution of the autolysin AtlA to the bactericidal activity of amoxicillin against Enterococcus faecalis JH2-2</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>1667</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19188384</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>WE</given-names></name><name><surname>Schulz</surname><given-names>LT</given-names></name><name><surname>Andes</surname><given-names>D</given-names></name><name><surname>Striker</surname><given-names>R</given-names></name><name><surname>Berti</surname><given-names>AD</given-names></name><name><surname>Hutson</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible <italic>Staphylococcus aureus</italic> during therapy improves antibacterial activity</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>5296</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">22869564</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>KH</given-names></name><name><surname>Houck</surname><given-names>HJ</given-names></name></person-group><article-title>Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><fpage>2871</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15273094</pub-id></element-citation></ref></ref-list></back></article>